

# **CODAN LIMITED**

# Material win for Tactical Communications

15 July 2019

BUY

Technology Hardware & Equipment / Electronic Equipment & Instruments

#### **COMPANY UPDATE**

Ticker	CDA
Stock Price	\$3.63
Target Price	\$3.96
Forecast Capital Return	9.1%
Forecast Dividend Yield	4.1%
Estimated Total Return - 12 Mth Forward	13.2%


### Company market data

Market Cap.	\$646.8m
Free Float (%)	61.8
Enterprise Value	\$633.8m
52 Week Range	\$2.79 - \$3.70
Shares Out.	178.2m
Avg. Daily Value	\$0.5m

Estimates changes	2018a	2019e	2020e	2021e
Core NPAT - old	39.8	44.6	45.5	49.6
Core NPAT - new	39.8	44.6	47.0	51.1
% Change	0.0	0.0	3.3	3.2
Core EPS dil. (¢) - old	22.1	24.8	25.3	27.5
Core EPS dil. (¢) - new	22.1	24.8	26.1	28.4
% Change	0.0	0.0	3.3	3.2
DPS (¢) - old	12.5	14.1	15.5	16.9
DPS (¢) - <i>new</i>	12.5	14.1	16.0	17.5
% Change	0.0	0.0	3.2	3.1

All figures are in AUD unless otherwise specified.

#### Share price performance



#### Analyst

Ronan Barratt +61 2 8288 5426 ronan.barratt@moelisaustralia.com

# EVENT

\$15m contact win within the Tactical Communications division.

Customer is the Government of Republic of Kenya, delivery 1H FY20.

#### IMPACT

Our FY20e NPAT increases by 3.3% to \$47.0m, reflecting an incremental \$2m of EBIT vs. our previous estimates within the Tactical Communications division from this contract win.

Our FY21e & FY22e NPAT also increase by ~3%, reflecting increased confidence in future sales execution from the Military 2 pipeline.

## **INVESTMENT VIEW**

We see this contract as good validation of CDA's longer-term strategy for Tactical Communications – to target the developing world army (or 'Military 2') market with a full communications platform.

We continue to be encouraged by the broadening of CDA's sales mix, with successful new product launches highlighting the ability for CDA to leverage its existing IP in order to access new addressable markets.

At ~14x NTM P/E, this IP remains undervalued in our view, especially when factoring the Minetec division is yet to be monetised and the Group's balance sheet capacity (~\$30m net cash) remains undeployed.

Our CDA investment thesis comprises:

**Growth potential across all business divisions** as a strong pipeline of new product releases supports the sales outlook and broadens the earnings base.

Minetec division on the cusp of commercialising product with CAT.

**World-leading hand-held Metal Detection with strong competitive advantages:** Market leading IP, well-established global distribution network in hard to reach locations, proven depth of product replacement cycle.

High & growing returns on invested capital (~22% ROIC).

**Proven track record of re-investing capital at high rates of return:** ~60% Return on Incremental Capital across FY16-FY19e.

~\$30m net cash balance sheet supporting acquisitions or enlarged dividends.

Maintain BUY. \$3.96 TP (prev: \$3.90).

Y/E Jun 30	2018a	2019e	2020e	2021
EBITDA	70.6	79.5	87.1	93.3
EV/EBITDA	9.0x	8.0x	7.3x	6.82
Core NPAT	39.8	44.6	47.0	51.1
Core EPS (Diluted) (¢)	22.1	24.8	26.1	28.4
P/E	16.4x	14.7x	13.9x	12.8:
EPS growth	(12.3%)	11.8%	5.4%	8.7%
DPS (¢)	12.5	14.1	16.0	17.5
Yield	3.4%	3.9%	4.4%	4.8%
DPS growth	(3.8%)	12.5%	13.6%	9.3%
Dividend Payout Ratio	56.4%	56.8%	61.2%	61.6%
All figures are in AUD.				

# **EARNINGS ESTIMATES**

Our earnings estimates by division are set out below:

# Figure 1: Earnings Estimates

	Actual	Estimates			
Profit and Loss	1H19a	2H19e	FY19e	FY20e	FY21e
EBIT					
Metal Detection	30	33	63	62	63
Radio	10	8	19	21	24
Mining Technology	0	(0)	(0)	2	6
Corporate	(9)	(11)	(20)	(22)	(24)
Group EBIT	30	30	61	64	69
Group EBIT Margin		23%	24%	24%	24%
NPAT	22.2	22.5	44.6	47.0	51.1
EPS	12.3	12.5	24.8	26.1	28.4
DPS	6.5	7.6	14.1	16.0	17.5

Source: Company, Moelis Analysis



Codan Limited (CDA)			Marl	cet Cap: \$6	647m	Last Price: \$3.63	Targ	et Price: \$3	3.96		Buy
Y/E Jun 30			Mail				range				
Profit and Loss (\$m)	2017a	2018a	2019e	2020e	2021e	Valuation Summary					
Revenue	226.1	229.9	256.8	270.1	293.1	Current Mkt Capitalisation					646.8
Growth	33.4%	1.7%	11.7%	5.2%	8.5%	Shares on Issue					178.2
EBITDA	75.7	70.6	79.5	87.1	93.3	Last Price					3.63
Growth	80.4%	(6.7%)	12.6%	9.5%	7.1%						
Dep'n & Amort	(14.1)	(16.7)	(18.9)	(23.4)	(24.1)	12 Mth Target Price					3.96
EBIT	61.6	53.9	60.6	63.6	69.2	Total Estimated 12 Mth Return					13.2%
Growth	110.7%	(12.5%)	12.4%	5.0%	8.7%	12 Mth Fwd Capital Return					9.1%
Net Interest Expense	(0.9)	(0.7)	0.6	1.0	1.3	12 Mth Fwd Dividend Yield					4.1%
Profit Before Tax	60.7	53.2	61.2	64.6	70.5						
Tax	(16.0)	(13.3)	(16.6)	(17.6)	(19.3)	Valuation Ratios	2017a	2018a	2019e	2020e	2021e
Tax Rate (%)	26.3%	25.1%	27.1%	27.2%	27.4%	EPS (Underlying) (¢)	25.2	22.1	24.8	26.1	28.4
Minorities	0.0	0.0	0.0	0.0	0.0	Growth	111.9%	(12.3%)	11.8%	5.4%	8.7%
NPAT (Underlying)	44.7	39.8	44.6	47.0	51.1						
Growth	112.0%	(10.9%)	12.0%	5.4%	8.7%	P/E (x)	14.4x	16.4x	14.7x	13.9x	12.8x
One-Off Items	0.0	0.0	0.0	0.0	0.0	Small Industrials (ex Fin's)	16.5x	19.3x	17.2x	15.6x	19.3x
NPAT (Reported)	44.7	39.8	44.6	47.0	51.1	Premium / (Discount)	(12.8%)	(15.0%)	(15.0%)	(10.9%)	(33.7%)
EPS (Underlying) (¢)	25.2	22.1	24.8	26.1	28.4	EV/EBITDA (x)	8.4x	9.0x	8.0x	7.3x	6.8x
Growth	111.9%	(12.3%)	11.8%	5.4%	8.7%	Small Industrials (ex Fin's)	11.0x	11.0x	11.8x	10.7x	9.9x
						Premium / (Discount)	(23.8%)	(18.4%)	(32.4%)	(31.8%)	(31.6%)
Balance Sheet (\$m)	2017a	2018a	2019e	2020e	2021e						
Cash	21.4	27.7	31.4	48.3	64.3	DPS (¢)	13.0	12.5	14.1	16.0	17.5
Inventory	31.0	31.6	41.1	44.3	48.1	Growth	116.7%	(3.8%)	12.5%	13.6%	9.3%
Current Receivables	20.6	29.8	30.8	33.2	36.1	Yield (%)	3.6%	3.4%	3.9%	4.4%	4.8%
PPE	12.0	12.5	14.1	14.8	15.7	Payout Ratio (%)	51.5%	56.4%	56.8%	61.2%	61.6%
Intangibles	140.4	146.4	150.7	152.2	155.0	Franking (%)	100.0%	100.0%	100.0%	100.0%	100.0%
Other	0.0	0.0	0.0	0.0	0.0						
Total Assets	232.7	254.3	274.5	299.1	325.6	NTA	24.6	41.7	50.8	69.3	87.3
Current Payables	36.6	46.3	51.4	55.4	60.2	NTA/Share (\$)	0.14	0.23	0.28	0.38	0.48
ST Debt	0.0	0.0	0.0	0.0	0.0						
LT Debt	0.0	0.0	0.0	0.0	0.0	Performance Ratios	2017a	2018a	2019e	2020e	2021e
Provisions	7.7	7.8	9.5	10.2	11.1	ROA	19.2%	15.7%	16.3%	15.7%	15.7%
Other	52.8	52.4	57.4	61.4	66.2	ROE	27.1%	21.2%	22.1%	21.2%	21.1%
Total Liabilities	67.7	66.2	73.0	77.7	83.3	ROIC	31.6%	25.2%	21.9%	26.7%	28.2%
Net Assets	165.0	188.1	201.5	221.5	242.3						
Equity & Reserves	105.9	107.0	100.9	102.3	103.2	Net Debt (Cash) (\$m)	(21.4)	(27.7)	(31.4)	(48.3)	(64.3)
Retained Profits	59.1	81.0	100.6	119.1	139.1	Net Debt/EBITDA (x)	(0.3x)	(0.4x)	(0.4x)	(0.6x)	(0.7x)
Shareholders' Equity	165.0	188.1	201.5	221.5	242.3	ND/(ND + Equity) (%)	(14.9%)	(17.3%)	(18.5%)	(27.9%)	(36.1%)
Minorities	0.0	0.0	0.0	0.0	0.0	Interest Cover (x)	84.6x	76.9x	120.7x	90.1x	72.5x
Total Equity	165.0	188.1	201.5	221.5	242.3						
						Working Capital	(1.0)	8.0	11.8	12.7	13.8
Cashflow (\$m)	2017a	2018a	2019e	2020e	2021e	Working Capital/Sales (%)	(0.5%)	3.5%	4.6%	4.7%	4.7%
EBITDA	75.7	70.6	79.5	87.1	93.3						
Net Interest	(0.8)	(0.5)	0.6	1.0	1.3	Cash Flow Metrics	2017a	2018a	2019e	2020e	2021e
Tax	(1.5)	(22.6)	(21.0)	(17.6)	(19.3)	FCF/Share (\$)	0.29	0.15	0.24	0.32	0.34
riangle in Working Capital	2.2	(0.1)	(5.5)	(1.6)	(1.9)	Price/FCPS (x)	12.4x	24.7x	15.1x	11.4x	10.7x
Other	14.4	0.8	1.7	0.7	0.9	Free Cash Flow Yield (%)	8.1%	4.1%	6.6%	8.8%	9.3%
Operating Cash Flow	89.9	48.2	55.3	69.6	74.1	Gross Cash Conversion	103.1%	101.2%	96.0%	100.1%	100.2%
Growth	86.5%	(46.4%)	14.6%	25.8%	6.6%	Capex/Sales (%)	(10.5%)	(9.6%)	(9.7%)	(9.5%)	(9.5%)
Capex	(23.7)	(22.0)	(24.8)	(25.6)	(27.8)	Capex/Depreciation (x)	1.7x	1.3x	1.3x	1.1x	1.2x
Acquisitions	0.0	0.0	0.0	0.0	0.0						
Divestments	0.0	0.0	0.0	0.0	0.0	Margins	2017a	2018a	2019e	2020e	2021e
Other	0.0	(0.5)	0.0	0.0	0.0	EBITDA	33.5%	30.7%	31.0%	32.2%	31.8%
Investing Cash Flow	(23.7)	(22.5)	(24.8)	(25.6)	(27.8)	EBIT	27.2%	23.5%	23.6%	23.6%	23.6%
Equity Raised	0.0	0.0	0.0	0.0	0.0	NPAT	19.8%	17.3%	17.4%	17.4%	17.4%
Dividends Paid	(17.7)	(19.6)	(26.7)	(27.1)	(30.3)						
Net Borrowings	(26.9)	0.0	0.0	0.0	0.0	Valuation Methodology					
Other	0.0	0.0	0.0	0.0	0.0	WACC (%)					10.0%
Financing Cash Flow	(44.7)	(19.6)	(26.7)	(27.1)	(30.3)	Discounted Cash Flow Valuation					3.70
FX / Non Cash Items	0.0	0.1	0.0	0.0	0.0	Sum-of-the-Parts Valuation					0.000
Change in Cash	21.6	6.3	3.7	16.9	16.0	Average Valuation					3.70
						10 Mill Transf Dates					3.96
						12 Mth Target Price					5.90

Source: Company data, IRESS, Moelis Australia research estimates

15-Jul-19



# **RESEARCH & SALES RESPONSIBILTIES**

Equities			Equities Research	
Simon Scott	Head of Equities	+612 8288 5418	Real Estate	
Elliot Leahey	Operations Manager	+612 8288 5402	Hamish Perks	+612 8288 5419
Jack Dyson	Desk Assistant	+612 8288 5401	Edward Day	+612 8288 5424
Jacqui Irons	Corporate Broking	+612 8288 5427	Ronan Barratt	+612 8288 5426
			Industrials	
Equities Sales & Tradin	g		Sean Kiriwan	+618 6555 8602
Ian McKenzie		+612 8288 5404	Sarah Mann	+612 8288 5407
Bryan Johnson		+612 8288 5412	Brendon Kelly	+612 8288 5413
Jason Bailey		+612 8288 5403	Tom Tweedie	+612 8288 5423
Andrew Harvey		+612 8288 5428		
Sam Clark		+612 8288 5410		
Mitchell Hewson - Head of Exec	cution	+612 8288 5417		
Aaron Payne - Real Estate		+612 8288 5405		

email: firstname.lastname@moelisaustralia.com

#### DISCLOSURE APPENDIX

## ANALYST CERTIFICATION

The Analyst, Ronan Barratt, responsible for the content of this research report, in whole or in part, certifies that with respect to the companies or securities that the individual analyses, that (1) the views expressed in this report accurately reflect his or her personal views on the subject companies and securities, and (2) no part of his or her compensation was, is, or will be directly or indirectly linked to the specific recommendations or views expressed in this research report.

I declare that:

- a) to the best of my knowledge I am not in receipt of inside information and the research does not contain inside information; and
- b) no other part of Moelis Australia has made any attempt to influence the research."


#### **RATING DEFINITIONS**

All companies under coverage are assigned a rating of Buy, Hold or Sell based on the expected 12 month total return estimated by the analyst(s). The total return is a combination of the estimated capital gain or loss, in addition to the estimated 12 month forward dividends or distributions. In relation to all companies that Moelis Australia Securities conducts research coverage on the relevant total return bands that derive the ratings are:

**Buy:** >15% **Hold:** 5% to 15% **Sell:** <5%.

### **RATINGS DISTRIBUTION TABLE**

#### Distribution of Ratings as at 15 July 2019



#### Rating and Price Target History: Codan Limited (CDA) as of 15/07/2019





# GENERAL TERMS OF USE FOR MOELIS RESEARCH REPORTS

Research reports have been prepared by Moelis Australia Securities Pty Ltd ("Moelis Securities"), ACN 122 781 560, AFS Licence 308 241, a Participant of the ASX Group and Chi-X and the intellectual property relating to the content vests with Moelis Securities unless otherwise noted.

#### GENERAL DISCLAIMER AND DISCLOSURES

#### Disclaimer

The information upon which this material is based was obtained from sources believed to be reliable, but has not been independently verified. Therefore, its accuracy is not guaranteed, and except to the extent that liability cannot be excluded. Moelis Securities does not accept any liability for any direct or consequential loss arising from relying upon the content in this document. This document is not an offer or solicitation of an offer to buy or sell any security or to make any investment. Any opinion or estimate constitutes the analyst's best judgement as of the date of preparation and is subject to change without notice. Due to changing market conditions, actual results may vary from forecast provided. Past performance is not an indication of future return, and loss of original capital may occur. Fluctuations in exchange rates could have adverse effects on the value or price of, or income from, certain investments.

This document is intended to provide general advice to wholesale investors only. No investment objectives, financial circumstances or needs of any individual have been taken into consideration in the preparation of this report. It does not purport to make any recommendation that any buying or selling is appropriate or any person's investment objectives or financial needs, and prior to making any investment decision a person should contact their professional advisors on whether or not any information in this document is appropriate to their individual circumstances.

This document is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or would subject Moelis Securities to any registration or licensing requirement within such jurisdiction. International Investors should contact their local regulatory authorities to determine whether any restrictions apply to their ability to purchase this investment. If you have received this document in error, please destroy it and any copies of it immediately.

#### Disclosure

Moelis Australia Limited, its officers, directors, employees, agents and authorized representatives may hold securities in any of the companies to which this document refers and may trade in the securities mentioned either as principal or as agent. Our sales and trading representatives may provide oral or written opinions that are contrary to the opinions expressed in this document. Our related body corporate Moelis Australia Advisory Pty Ltd ("Moelis Advisory"), may make statements or provide advisory services to the company to which this document refers and such statements may be contrary to the views or recommendations expressed in this document. Moelis Advisory may have previously been appointed by CDA to provide corporate advisory services for which it may have received compensation. Moelis Advisory may be appointed by CDA to provide corporate advisory services in the future for which it may receive compensation. The analyst responsible for this document has taken reasonable care to achieve and maintain independence and objectivity and certifies that no part of their compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. The compensation of the analyst is based on overall revenues of Moelis Securities and its related entities. The analyst may also interact with trading desk personnel, sales personnel and other parties for the purpose of gathering, applying and interpreting market information. In producing research reports, the analyst may attend site visits and other meetings hosted by the issuers the subject of its research report. In some instances the costs of such site visits or meeting may be met in part or in whole by the issuers concerned if Moelis Securities considers it is appropriate and reasonable in the specific circumstance relating to the site visit or meeting and will not comprise the integrity of the research report.

Moelis Securities is a trading participant of the ASX Group and Chi-X and earns fees and commissions from dealing in the relevant financial product.

#### General U.S. Disclaimer

This report is a product of Moelis Securities, which is the employer of the research analyst(s) who has prepared the report. The research analyst(s) preparing the report is/are resident outside the United States of America (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is not intended for use by, or distribution to, persons in the U.S. that do not meet the definition of a major U.S. institutional investor under Rule 15a-6 under the U.S. Securities Exchange Act of 1934 ("Rule 15a-6"). The financial instruments described herein may not have been registered under the U.S. Securities Act of 1933 (the "Securities Act") and may not be offered or sold in the U.S. unless they have been registered under the Securities Act, or pursuant to an exemption from, or in transactions not subject to, the registration requirements of the Securities Act, and in compliance with any applicable securities laws of any state or other jurisdiction of the U.S.. This report has been prepared by Moelis Securities and is being distributed to major U.S. institutional investors pursuant to Rule 15a-6(a)(2).

Any U.S. Persons or recipients of this Report located in the U.S. that are interested in trading the financial instruments referred to in this report should only effect such transactions through a U.S.-registered broker-dealer.

The distribution of this report in certain jurisdictions may be prohibited or restricted by rules, regulations and/or laws of such jurisdictions and persons into whose possession this presentation comes should inform themselves about and observe any such restrictions. Any failure to comply with such prohibitions or restrictions may constitute a violation of the laws of such other jurisdictions.